Program
fezolinetant
Also written as “Fezolinetant”, “fezolinetant - test formulation” and “fezolinetant - reference formulation”.
Its studies are mostly in Hot Flashes · Prostatic Neoplasms · Renal Insufficiency, led by Astellas Pharma.
Drug pageFezolinetant: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 213 open or running | phase 3since Jun 27, 2019 | Jun 15, 2017 | Apr 30, 2027phase 1 · NCT07783282 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Jun 15, 2017 to Jun 27, 2019.
- Jun 9, 2016Named fezolinetantINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ESN364
- Jan 16, 2020Phase 3 study in Hot FlashesNCT04234204 · 302 enrolled · China, Korea, Republic of, Taiwan
- Feb 18, 2020Phase 1 study in Healthy VolunteersNCT04277624 · 22 enrolled · United States
- Jun 26, 2020Phase 3 study in Hot FlashesNCT04451226 · 150 enrolled · China
- Jul 15, 20202 phase 1 studiesNCT04476849, NCT04482270
- Nov 20, 2020Phase 1 study in Healthy SubjectsNCT04641260 · 16 enrolled · United States
- Mar 9, 2021Phase 1 study in Healthy VolunteersNCT04793204 · 16 enrolled · China
- Sep 1, 2021Phase 2 study in Hot FlashesNCT05034042 · 147 enrolled · Japan
- Sep 1, 2021Phase 3 study in Vasomotor SymptomsNCT05033886 · 453 enrolled · Belgium, Canada, Czechia and more
- Jun 6, 2022Phase 2 study in Hot FlashesNCT05419908 · 87 enrolled · Belgium
- Jan 4, 20242 phase 3 studies in Hot FlashesNCT06206421, NCT06206408
- May 29, 2024Phase 3 study in Hot FlashesNCT06440967 · 982 enrolled · Canada, Czechia, Denmark and more
- Feb 3, 2025Phase 2 study in Hot FlashesNCT06812754 · 150 enrolled · China
- Aug 20, 2026Phase 1 study in Prostatic NeoplasmsNCT07783282 · 56 planned · Bulgaria
- Sep 15, 2026Phase 3 study in Hot FlashesNCT07829653 · 100 planned · India
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07783282
- Mar 31, 2028Primary completion: phase 3 study in Hot FlashesNCT07829653
TargetBeta
“An orally bioavailable, neurokinin/tachykinin 3 receptor (NK1-receptor; NK3R; NK-3R) antagonist, that can be used to treat vasomotor symptoms (VMS) in menopausal woman”NCIt, by rule
“Neurokinin 3 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elinzanetantrule | Bayer | phase 3 | 24 |
| GS1-144rule | Changchun GeneScience Pharmaceutical | phase 2 | 6 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07829653Hot Flashes · India | 3 | Recruiting | Mar 31, 2028 | 100 |
| NCT07783282Prostatic Neoplasms · Bulgaria | 1 | Recruiting | Apr 30, 2027 | 56 |
| NCT06812754Hot Flashes · China | 2 | Completed | Feb 11, 2026 | 150 |
| NCT06440967Hot Flashes · Canada, Czechia, Denmark and more | 3 | Active, not recruiting | Jun 25, 2026 | 982 |
| NCT06206421Hot Flashes · Japan | 3 | Completed | Mar 19, 2026 | 277 |
| NCT06206408Hot Flashes · Japan | 3 | Completed | Oct 22, 2025 | 410 |
| NCT05419908Hot Flashes · Belgium | 2 | Completed | Sep 21, 2016 | 87 |
| NCT05034042Hot Flashes · Japan | 2 | Completed | Nov 11, 2022 | 147 |
| NCT05033886Vasomotor Symptoms · Belgium, Canada, Czechia and more | 3 | Completed | Mar 27, 2023 | 453 |
| NCT04793204Healthy Volunteers · China | 1 | Completed | May 21, 2021 | 16 |
| NCT04641260Healthy Subjects · United States | 1 | Completed | Feb 12, 2021 | 16 |
| NCT04482270Hepatic Impairment · United States | 1 | Completed | Mar 22, 2021 | 26 |
| NCT04476849Renal Insufficiency · United States | 1 | Completed | Mar 6, 2022 | 27 |
| NCT04451226Hot Flashes · China | 3 | Completed | Jun 13, 2022 | 150 |
| NCT04277624Healthy Volunteers · United States | 1 | Completed | Feb 21, 2021 | 22 |
| NCT04234204Hot Flashes · China, Korea, Republic of, Taiwan | 3 | Completed | Apr 20, 2022 | 302 |
| NCT04003389Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Jan 4, 2022 | 1,831 |
| NCT04003155Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Oct 29, 2020 | 527 |
| NCT04003142Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Jul 30, 2020 | 501 |
| NCT03436849Healthy Subjects · Japan | 1 | Completed | May 23, 2018 | 44 |
| NCT03192176Hot Flashes · United States | 2 | Completed | Sep 19, 2018 | 356 |
How it is read
Names in the registry
- “Fezolinetant”, 12 entries
- “fezolinetant”, 7 entries
- “fezolinetant - test formulation”, 1 entry
- “fezolinetant - reference formulation”, 1 entry
- “ESN364”, 1 entry
Conditions, from the studies’ own filings
- Hot Flashes, 13 studies
- Prostatic Neoplasms, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.